AUTOLUS THERAPEUTICS LTD

NASDAQ: AUTL (Autolus Therapeutics plc)

Kemas kini terakhir: 29 May, 10:10AM

1.76

0.11 (6.36%)

Penutupan Terdahulu 1.65
Buka 1.69
Jumlah Dagangan 810,755
Purata Dagangan (3B) 1,968,232
Modal Pasaran 467,077,440
Harga / Jualan (P/S) 33.53
Harga / Buku (P/B) 0.830
Julat 52 Minggu
1.11 (-37%) — 5.00 (184%)
Tarikh Pendapatan 8 Aug 2025 - 22 Aug 2025
Margin Operasi (TTM) -261,600.00%
EPS Cair (TTM) -0.860
Pertumbuhan Hasil Suku Tahunan (YOY) 681.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 69.56%
Nisbah Semasa (MRQ) 10.88
Aliran Tunai Operasi (OCF TTM) -206.27 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -187.04 M
Pulangan Atas Aset (ROA TTM) -25.99%
Pulangan Atas Ekuiti (ROE TTM) -81.91%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Autolus Therapeutics plc Menaik Bercampur

AISkor Stockmoo

1.9
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 1.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AUTL 467 M - - 0.830
LEGN 6 B - - 5.85
MTSR 3 B - - -
IMCR 2 B - - 4.94
GYRE 768 M - 425.00 11.27
BCAX 631 M - - 1.37

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 18.09%
% Dimiliki oleh Institusi 86.02%

Pemilikan

Nama Tarikh Syer Dipegang
Syncona Portfolio Ltd 31 Dec 2024 16,640,720
34.0034.0026.5026.5019.0019.0011.5011.504.004.00Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
1.11 (-37%) — 5.00 (184%)
Julat Harga Sasaran
6.00 (241%) — 10.00 (469%)
Tinggi 10.00 (Truist Securities, 469.80%) Beli
10.00 (Needham, 469.80%) Beli
Median 10.00 (469.80%)
Rendah 6.00 (Wells Fargo, 241.88%) Beli
Purata 8.67 (394.02%)
Jumlah 3 Beli
Harga Purata @ Panggilan 1.82
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Needham 12 Jun 2025 10.00 (469.80%) Beli 2.34
10 Apr 2025 10.00 (469.80%) Beli 1.14
Truist Securities 01 Apr 2025 10.00 (469.80%) Beli 1.41
Wells Fargo 21 Mar 2025 6.00 (241.88%) Beli 1.70

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
12 Jun 2025 Pengumuman Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
29 May 2025 Pengumuman Autolus Therapeutics to Participate in Upcoming Investor Conferences
23 May 2025 Pengumuman Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
14 May 2025 Pengumuman Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
08 May 2025 Pengumuman Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
25 Apr 2025 Pengumuman Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
23 Apr 2025 Pengumuman Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
22 Apr 2025 Pengumuman Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
02 Apr 2025 Pengumuman Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
01 Apr 2025 Pengumuman Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
24 Mar 2025 Pengumuman Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
20 Mar 2025 Pengumuman Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Papar semua
2.522.522.162.161.811.811.451.451.091.09May 28May 28May 29May 29May 30May 30Jun 2Jun 2Jun 3Jun 3Jun 4Jun 4Jun 5Jun 5Jun 6Jun 6

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.4000.4000.3000.3000.2000.2000.1000.1000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda